{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:12:00Z","timestamp":1789157520158,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cardfail.2026.08.011","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:39:03Z","timestamp":1787269143000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"AHMAD","family":"MASRI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GREGORY D.","family":"LEWIS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROBERTO","family":"BARRIALES-VILLA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRIAN L.","family":"CLAGGETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLINE J.","family":"COATS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PERRY","family":"ELLIOTT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALBERT","family":"HAG\u00c8GE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-1088","authenticated-orcid":false,"given":"IAN J.","family":"KULAC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PABLO","family":"GARCIA-PAVIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL A.","family":"FIFER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BENJAMIN","family":"MEDER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"IACOPO","family":"OLIVOTTO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHAEL A.","family":"NASSIF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6458-5421","authenticated-orcid":false,"given":"NEAL K.","family":"LAKDAWALA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANJALI T.","family":"OWENS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-1474","authenticated-orcid":false,"given":"STEPHEN B.","family":"HEITNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL L.","family":"JACOBY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"REGINA","family":"SOHN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-1287","authenticated-orcid":false,"given":"STUART","family":"KUPFER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-5759","authenticated-orcid":false,"given":"FADY I.","family":"MALIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AMY","family":"WOHLTMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARTIN S.","family":"MARON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.08.011_bib0001","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","article-title":"Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy","volume":"8","author":"Coats","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0002","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ahj.2015.02.006","article-title":"Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography","volume":"169","author":"Masri","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0003","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0004","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jchf.2024.11.011","article-title":"Aficamten vs metoprolol for obstructive hypertrophic cardiomyopathy: MAPLE-HCM rationale, study design, and baseline characteristics","volume":"13","author":"Garcia-Pavia","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0008","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"84","author":"Sherrod","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0009","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","article-title":"Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial","volume":"45","author":"Coats","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0010","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0011","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0012","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamacardio.2024.2781","article-title":"Aficamten and cardiopulmonary exercise test performance: a substudy of the SEQUOIA-HCM randomized clinical trial","volume":"9","author":"Lee","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0013","series-title":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","year":"2009"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0014","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0015","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0016","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0017","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of aficamten on disease and symptom burden in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"84","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.08.011_bib0018","doi-asserted-by":"crossref","unstructured":"Wang A, Garcia-Pavia P, Masri A, et al. Aficamten in obstructive hypertrophic cardiomyopathy: a multidomain, patient-level analysis of the MAPLE-HCM Trial.J Am Coll Cardiol 2025. S0735\u20131097(25)10068\u20135 doi:10.1016\/j.jacc.2025.10.057.","DOI":"10.1016\/j.jacc.2025.10.057"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426005002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:53:57Z","timestamp":1789156437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426005002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":18,"alternative-id":["S1071916426005002"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.08.011","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Threshold for a Clinically Meaningful Improvement in Cardiopulmonary Exercise Testing Measures for Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}